Yes, albumin infusion should be administered in hepatorenal syndrome (HRS) even when serum albumin levels are normal.
In patients with hepatorenal syndrome-acute kidney injury (HRS-AKI), albumin infusion is recommended as part of standard treatment regardless of baseline serum albumin levels. The rationale for albumin use in HRS is not to correct hypoalbuminemia, but rather to expand central circulation and enhance the effects of vasoconstrictor therapy on renal blood flow 1.
Mechanism and Rationale
The pathophysiology of HRS-AKI involves extreme splanchnic vasodilation leading to low effective arterial blood volume, with subsequent renal vasoconstriction and decreased glomerular filtration rate 1. Albumin works by:
- Filling the central circulation to enhance vasoconstrictor effects on improving renal blood flow
- Potentially attenuating systemic inflammatory responses beyond simple volume expansion 1
- Supporting oncotic pressure to counteract the hemodynamic derangements
Evidence-Based Dosing
Most pivotal trials comparing terlipressin with placebo used albumin at 20-40 g/day during vasoconstrictor treatment 1. However, the evidence suggests:
- The benefit of albumin is likely achieved after a short course of 1-2 days of administration 1
- A dose-response relationship exists, with higher cumulative albumin doses associated with improved survival 2
- Expected 30-day survival rates increase from 43.2% with 200g cumulative dose to 59.0% with 600g cumulative dose 2
Critical Practice Points
The need for continuation of albumin beyond the initial 1-2 days should be assessed carefully based on volume status, not serum albumin levels 1. Point-of-care ultrasonography has been suggested as an optimal monitoring method 1.
When to Use Albumin in HRS-AKI:
- Terlipressin is the vasoactive drug of choice, and concurrent albumin can be considered when accounting for the patient's volume status 1
- Start treatment early when creatinine is <5 mg/dL, as higher levels have low response rates 1
- One small study (n=21) suggested terlipressin without albumin is less effective than combination therapy 1
Important Caveats:
- Monitor for fluid overload, particularly in patients with severe liver dysfunction 3
- Patients with infection as an AKI precipitant may require higher albumin doses (>50 g/day) without increased adverse outcomes 3
- Respiratory failure from albumin is rare and typically related to underlying conditions (pneumonia, aspiration) rather than albumin itself 3
Guideline Concordance
Multiple 2024 guidelines support albumin use in HRS 1, 4. The FDA label for albumin lists hepatorenal syndrome as an indication, noting that albumin administration "may serve the double purpose of supporting the colloid osmotic pressure of the plasma as well as binding excess plasma bilirubin" 5.
The key distinction is that albumin in HRS is a hemodynamic intervention, not nutritional supplementation 5. The FDA explicitly states that "in hypoproteinemic states associated with chronic cirrhosis...the infusion of albumin as a source of protein nutrition is not justified" 5.